Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Inhibrx, Inc.
  6. News
  7. Summary
    INBX   US45720L1070

INHIBRX, INC.

(INBX)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
27.19 USD   -2.96%
12/07Insider Sell: Inhibrx
MT
11/22Insider Sell: Inhibrx
MT
11/18Insider Sell: Inhibrx
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inhibrx Shares Rise 33% After FDA Talks on INBRX-101

10/04/2022 | 12:32pm EST

By Chris Wack


Inhibrx Inc. shares were up 33% to $26.85 after the company said that based on discussions with the U.S. Food and Drug Administration, there is potential to pursue an accelerated approval in the U.S. for INBRX-101.

The stock closed Monday up 12%, and is up 132% in the last three months.

INBRX-101 is an optimized recombinant human AAT-Fc fusion protein for patients with emphysema due to alpha-1 antitrypsin deficiency using functional alpha-1 antitrypsin serum levels as the surrogate endpoint.

Inhibrx also said it detected INBRX-101 in the bronchoalveolar lavage fluid samples from all alpha-1 antitrypsin deficiency patients tested in the Phase 1 study.

The company said it plans to initiate in the first quarter of 2023 a potential registration-enabling clinical trial using functional AAT as a surrogate endpoint with the intent to submit for regulatory approval under the FDA's accelerated approval program. The FDA expressed support to collaborate and work with Inhibrx to address the regulatory challenges associated with AATD drug development, the company said.

It said the FDA emphasized the importance of being able to demonstrate INBRX-101's ability to maintain a trough level within the normal range of AAT in healthy individuals.

The FDA also requested additional data on the correlation between functional AAT levels and the clinical benefit in AATD to further support serum AAT levels as a surrogate endpoint that is reasonably likely to predict clinical benefit, the prerequisite for accelerated approval, Inhibrx said.

On Monday, the company amended the milestone terms of the last remaining tranche under its loan and security agreement with Oxford Finance LLC to provide for the funding of $30 million upon the announcement of the regulatory path for INBRX-101 rather than upon the initiation of a potential registration-enabling clinical trial of INBRX-101. The company has 30 days from this announcement to initiate this draw.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

10-04-22 1231ET

All news about INHIBRX, INC.
12/07Insider Sell: Inhibrx
MT
11/22Insider Sell: Inhibrx
MT
11/18Insider Sell: Inhibrx
MT
11/18Inhibrx Announces Participation in Upcoming Investor Conference
PR
11/16Inhibrx Shares Updated Data from Phase 1 Trial of INBRX-109 in Bone Cancer
MT
11/16Inhibrx, Inc. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ..
AQ
11/16Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Ph..
PR
11/16Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion..
CI
11/08Credit Suisse Lowers Inhibrx's Price Target to $46 From $48, Keeps Outperform Rating
MT
11/07Earnings Flash (INBX) INHIBRX Posts Q3 Revenue $278,000
MT
More news
Analyst Recommendations on INHIBRX, INC.
More recommendations
Financials (USD)
Sales 2022 2,60 M - -
Net income 2022 -139 M - -
Net cash 2022 77,0 M - -
P/E ratio 2022 -8,09x
Yield 2022 -
Capitalization 1 184 M 1 184 M -
EV / Sales 2022 426x
EV / Sales 2023 192x
Nbr of Employees 109
Free-Float 71,8%
Chart INHIBRX, INC.
Duration : Period :
Inhibrx, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INHIBRX, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 27,19 $
Average target price 47,50 $
Spread / Average Target 74,7%
EPS Revisions
Managers and Directors
Mark P. Lappe Chairman & Chief Executive Officer
Kelly Devine Deck Chief Financial Officer
Brendan P. Eckelman Chief Scientific Officer
Ashraf Amanullah Chief Technical Operations Officer & Executive VP
Jeffrey Jensen Executive Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
INHIBRX, INC.-35.84%1 220
VERTEX PHARMACEUTICALS44.62%82 480
REGENERON PHARMACEUTICALS, INC.21.02%81 748
BIONTECH SE-33.36%41 753
WUXI APPTEC CO., LTD.-32.53%33 492
GENMAB A/S23.08%29 964